Investor Center

Press Releases

Press Releases

February 5, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2020-- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of its initial public offering of 10,588,236 shares of common stock at a public offering price
Displaying 11 - 13 of 13